Dyax will complete its rolling BLA submission for its DX-88 investigational treatment for hereditary angioedema early in the fourth quarter, based on positive results from a second Phase III trial.  Read More

ImClone Systems has treated its first patient in a Phase III clinical trial of IMC-1121B, its antivascular endothelial growth factor receptor-2 monoclonal antibody, in women with metastatic breast cancer.  Read More

Bioniche Life Sciences has received positive feedback from its data safety monitoring committee for the company’s first Phase III clinical trial using Urocidin to treat non-muscle-invasive bladder cancer.  Read More

Using polysaccharide technology licensed from Stellar Pharmaceuticals, Watson Pharma has successfully concluded its Phase III study with Uracyst for patients with interstitial cystitis (IC).  Read More

Dendreon has started the second of two Phase II trials using Provenge, an investigational active cellular immunotherapy, for the treatment of advanced prostate cancer.  Read More

Patients allergic to dust mites halved their consumption of inhaled steroids by using ALK-Abello’s investigational vaccine tablets in a Phase II/III study.  Read More

Medarex and its partner MedImmune have initiated a Phase IIa clinical trial of MEDI-545 for the treatment of systemic lupus erythematosus.  Read More

Palatin Technologies completed its Phase IIa clinical trial of PL-3994, a long-acting natriuretic peptide receptor A agonist for treating heart failure.  Read More

As part of a licensing agreement with Can-Fite BioPharma, Seikagaku (SKK) will begin a Phase I trial in Japan using Can-Fite’s CF101 to treat rheumatoid arthritis (RA).  Read More

Micromet received positive results in its Phase I study of blinatumomab in patients with relapsed lymphoma.  Read More